Market News Latest

Cytologics Launches New Immune Cell Products for Research

 Breaking News
  • No posts were found

Cytologics Launches New Immune Cell Products for Research

June 20
17:56 2022

Cytologics, the leading provider of human immune cells, blood products and related services for the life sciences industry, announced today the launch of their expanded biospecimen registry. The registry allows scientists to search for optimal immune cell products from a large and diverse donor base to meet their research needs. The company explained that biotech companies and academic researchers have long experienced difficulty in sourcing high-quality and regulatory-compliant immune cell products due to the shortage of suppliers.

As such, Cytologics has taken the bold step to ensure an abundant provision of human immune cell products, including isolated PBMCs, Pan T cells, cytotoxic T cells, NK cells and B cells. Researchers no longer need to worry about the challenges of procuring high-quality cell products and blood components for research. They can also purchase frozen cell pellets in bulk for large-scale studies and request custom cell processing.

Addressing the need for a premium, trustworthy supply of immune cells, a spokesperson for the company said, “Our commitment to advancing scientific discovery has compelled us to expand our donor base and product portfolio. This ensures customers across the entire cell and gene therapy lifecycle—from discovery to cure—have access to the biospecimens they need to conduct their research.”

“From biomarker studies to cell-based assays, our immune cell products are the ideal choice for scientists. Every product is guaranteed for high cell viability and yield in accordance with the certificate of analysis.” Cytologicsis well-positioned to meet growing demand, thanks to a team of industry experts, a world-class cell processing laboratory, and a large network of well-characterized donors. Upon placing an order, researchers can track the biospecimen collection and delivery process to ensure no delay in completing their research.

Each order is tailored to the client’s specifications, including donor demographics, HLA type, isolation procedure and cell count per vial. Cytologics operates under a stringent quality system (the Cytologics Quality System or “CQS”) which ensures products are thoroughly examined to meet client requirements and industry standards prior to shipping.

The spokesperson further commented, “We believe that no matter how difficult the request, researchers can trust Cytologics to identify the right donor, isolate and characterize specific immune cells, and deliver exceptional service. That’s why we’ve invested heavily in our team of industry experts who constantly develop and improve our procedures. Our products will benefit both researchers and clinical teams, especially those who are looking for cells derived from buffy coats, leukapheresis or whole blood.

Given the cost, difficulty, and time required for cell processing and isolation, Cytologics has streamlined the process by investing in high-quality equipment and employing cutting-edge technology. Thus, product variability, which is one common cause of failed cell studies, is significantly reduced. Moreover, the company’s strict standards and quality control testing guarantee contaminant-free and top-quality products customers can trust.

About Cytologics

Founded in 2018, Cytologics provides ethically sourced and high-quality human biological material for researchers developing new therapies and diagnostics. With coast-to-coast collection facilities, the company’s team of trained and certified experts oversees each step of the process, from cell sourcing to delivering the final product.

Visit https://cytologicsbio.com to learn how Cytologics can support your research and development.

Media Contact
Company Name: Cytologics
Contact Person: Media Relations
Email: Send Email
Phone: +1 866 298 6077
Country: United States
Website: https://cytologicsbio.com/